One professional psychiatrist shares his account of living with bipolar affective disorder.
This randomized, placebo-controlled, phase 3 clinical trial showed that a 14-day treatment course of oral zuranolone 50 mg/day in MDD led to significantly greater improvements in depressive symptoms when compared with placebo.
D-cycloserine may help patients with anxiety disorders, or it might make their anxiety worse. Find out how to use it safely.
How can looking at the suffering of patients with schizophrenia through a psychodynamic lens help clinicians develop effective interventions and treatment plans?
What is the mindset of “anti-vaxxers,” and how can you connect with them as a clinician?
We need policies that make digital therapeutics accessible and acceptable to a broad patient audience. What barriers are there to reaching that goal?
Collecting fees is essential, but it can be uncomfortable and even difficult. What strategies can you use to ease the burden?
Caring for physician-patients can be a challenge…
This moment in history cannot be lost. When you ask us if we are okay, be prepared to hear us say we are not . . . and never have been. Then be prepared to do more.
Online environments have revolutionized the lives of young SGM individuals, but also created unforeseen issues...
"Organized medicine and specialty organizations are key pillars of support for individual physicians that provide opportunities to advocate for more funding and resources for the medical system and education."
Are you ready to discuss the Black youth crisis and the need for dynamic conversations?
Given that two-thirds of patients treated for a major depressive episode will fail to achieve remission of symptoms after 2 or more treatment trials of first-line antidepressants, the probability of remission will further decrease with subsequent medication trials. Treatment strategies for patients with TRD include augmentation, where a medication is added to a current antidepressant versus switching to a different antidepressant.
Which is the best recommendation for the treatment of alcohol use disorder?
How can you communicate the diagnosis in a way that relieves suffering and helps patients and their caregivers prepare for the future?
The COVID-19 pandemic has disproportionately affected people of color due to legal, social, and economic inequities.
Clinicians can ensure high-quality care by remaining informed about legal and ethical considerations in navigating patient privacy dilemmas.
Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.
Considering challenges and opportunities in digital health solutions for mental health care.
Whether a patient has a diagnosis of cPTSD, BPD, or some combination of both, treatment should be considered multifaceted and overlapping. Learn more in this Special Report article.
This book provides a comprehensive overview of the most sustained comprehensive mental health recovery and research program implemented after a natural disaster.
Addiction among older adults is associated with worse medical outcomes and increased economic burden of care. The long-term use of psychoactive substances can result in adverse neurological outcomes even at therapeutic doses.
How can offering hope for chronic illness make healing possible for us all?
How is the Sigourney Award helping expand the boundaries of psychoanalytic thinking?
Loss of smell can be devastating for patients. How can psychiatrists deal with the associated psychological effects?
How can we, as clinicians, understand how trauma has affected our patients and respond in the most effective way?